Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.01 Insider Own3.48% Shs Outstand16.67M Perf Week-19.84%
Market Cap8.42M Forward P/E- EPS next Y-3.67 Insider Trans0.00% Shs Float16.09M Perf Month-55.51%
Income-45.17M PEG- EPS next Q-0.73 Inst Own30.55% Short Float / Ratio0.26% / 0.78 Perf Quarter-75.95%
Sales11.87M P/S0.71 EPS this Y26.22% Inst Trans-15.85% Short Interest0.04M Perf Half Y-86.64%
Book/sh-0.05 P/B- EPS next Y-34.99% ROA-77.05% Target Price15.67 Perf Year-79.96%
Cash/sh2.45 P/C0.21 EPS next 5Y- ROE-426.46% 52W Range0.49 - 4.69 Perf YTD-71.94%
Dividend- P/FCF- EPS past 5Y14.32% ROI-190.93% 52W High-89.23% Beta1.43
Dividend %- Quick Ratio2.11 Sales past 5Y-20.00% Gross Margin- 52W Low3.06% ATR0.09
Employees34 Current Ratio2.11 Sales Q/Q- Oper. Margin-372.82% RSI (14)18.10 Volatility11.20% 11.57%
OptionableYes Debt/Eq- EPS Q/Q27.95% Profit Margin-380.49% Rel Volume1.15 Prev Close0.50
ShortableYes LT Debt/Eq- EarningsOct 27 BMO Payout- Avg Volume53.85K Price0.50
Recom1.00 SMA20-38.55% SMA50-54.91% SMA200-80.66% Volume62,094 Change1.00%
Date Action Analyst Rating Change Price Target Change
Jul-09-21Initiated Jefferies Buy $8
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Nov-20-23 07:00AM
Nov-03-23 07:00AM
Oct-27-23 08:00AM
Oct-24-23 08:00AM
Oct-18-23 07:00AM
09:30AM Loading…
Oct-13-23 09:30AM
Sep-22-23 07:00AM
Sep-07-23 07:00AM
Aug-11-23 07:00AM
Jul-07-23 10:42AM
Jul-06-23 11:09AM
Jul-05-23 04:30PM
Jun-23-23 07:00AM
Jun-22-23 07:30AM
07:00AM Loading…
Jun-01-23 07:00AM
May-18-23 07:00AM
May-15-23 07:00AM
Apr-28-23 07:00AM
Apr-27-23 09:40AM
Apr-24-23 07:00AM
Apr-05-23 09:40AM
Mar-28-23 07:00AM
Mar-24-23 07:00AM
Mar-22-23 07:00AM
Mar-20-23 09:40AM
Mar-14-23 07:00AM
Mar-13-23 07:54AM
Mar-10-23 07:00AM
Mar-09-23 09:55AM
07:00AM Loading…
Mar-08-23 07:00AM
Mar-02-23 09:40AM
Feb-28-23 07:00AM
Feb-24-23 06:00AM
Jan-03-23 07:00AM
Dec-22-22 11:34AM
Dec-19-22 01:53PM
Dec-16-22 07:00AM
Dec-15-22 07:00AM
Nov-21-22 07:00AM
Nov-10-22 02:17PM
Nov-09-22 10:17AM
Nov-08-22 07:00AM
Oct-28-22 07:00AM
Sep-28-22 10:24AM
Sep-14-22 11:05AM
Sep-13-22 07:00AM
Sep-07-22 06:00AM
Sep-02-22 07:00AM
Aug-25-22 07:03AM
Aug-22-22 07:00AM
Aug-12-22 07:00AM
Aug-11-22 07:00AM
Jun-07-22 07:00AM
Jun-06-22 07:00AM
May-31-22 07:00AM
May-20-22 07:00AM
May-18-22 07:00AM
May-10-22 07:00AM
Apr-27-22 07:00AM
Apr-06-22 07:00AM
Apr-01-22 05:00PM
Mar-28-22 07:00AM
Mar-25-22 07:00AM
Mar-18-22 07:00AM
Mar-15-22 07:00AM
Jan-21-22 10:55AM
Jan-20-22 04:05PM
Jan-18-22 08:06AM
Jan-11-22 07:00AM
Jan-06-22 07:00AM
Dec-06-21 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Oct-26-21 07:00AM
Oct-22-21 07:00AM
Oct-18-21 07:00AM
Oct-14-21 07:00AM
Sep-28-21 10:11AM
Sep-27-21 02:30PM
Sep-22-21 07:00AM
Sep-21-21 07:00AM
Sep-13-21 08:38AM
Sep-09-21 07:00AM
Aug-06-21 07:00AM
Aug-04-21 07:00AM
Jul-27-21 10:38PM
Jul-13-21 07:00AM
Jul-09-21 06:08PM
Jun-14-21 07:11AM
Jun-08-21 09:04AM
Jun-04-21 09:04AM
May-25-21 07:30AM
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.